250 related articles for article (PubMed ID: 27494876)
1. Xanthine oxidoreductase is required for genotoxic stress-induced NKG2D ligand expression and gemcitabine-mediated antitumor activity.
Xu X; Rao G; Li Y
Oncotarget; 2016 Sep; 7(37):59220-59235. PubMed ID: 27494876
[TBL] [Abstract][Full Text] [Related]
2. Uric acid accumulation in DNA-damaged tumor cells induces NKG2D ligand expression and antitumor immunity by activating TGF-β-activated kinase 1.
Wang J; Liu K; Xiao T; Liu P; Prinz RA; Xu X
Oncoimmunology; 2022; 11(1):2016159. PubMed ID: 35154904
[TBL] [Abstract][Full Text] [Related]
3. Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression.
Xu X; Rao GS; Groh V; Spies T; Gattuso P; Kaufman HL; Plate J; Prinz RA
BMC Cancer; 2011 May; 11():194. PubMed ID: 21605422
[TBL] [Abstract][Full Text] [Related]
4. Xanthine oxidoreductase mediates genotoxic drug-induced autophagy and apoptosis resistance by uric acid accumulation and TGF-β-activated kinase 1 (TAK1) activation.
Wang J; Hu Y; Liu P; Xu X
FASEB J; 2023 Feb; 37(2):e22723. PubMed ID: 36583708
[TBL] [Abstract][Full Text] [Related]
5. CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells.
Sauer M; Schuldner M; Hoffmann N; Cetintas A; Reiners KS; Shatnyeva O; Hallek M; Hansen HP; Gasser S; von Strandmann EP
Oncogene; 2017 Feb; 36(7):933-941. PubMed ID: 27477692
[TBL] [Abstract][Full Text] [Related]
6. HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines.
Okita R; Mougiakakos D; Ando T; Mao Y; Sarhan D; Wennerberg E; Seliger B; Lundqvist A; Mimura K; Kiessling R
J Immunol; 2012 Mar; 188(5):2136-45. PubMed ID: 22301547
[TBL] [Abstract][Full Text] [Related]
7. NZ28-induced inhibition of HSF1, SP1 and NF-κB triggers the loss of the natural killer cell-activating ligands MICA/B on human tumor cells.
Schilling D; Kühnel A; Tetzlaff F; Konrad S; Multhoff G
Cancer Immunol Immunother; 2015 May; 64(5):599-608. PubMed ID: 25854583
[TBL] [Abstract][Full Text] [Related]
8. NKG2D-dependent activation of dendritic epidermal T cells in contact hypersensitivity.
Nielsen MM; Dyring-Andersen B; Schmidt JD; Witherden D; Lovato P; Woetmann A; Ødum N; Poulsen SS; Havran WL; Geisler C; Bonefeld CM
J Invest Dermatol; 2015 May; 135(5):1311-1319. PubMed ID: 25634359
[TBL] [Abstract][Full Text] [Related]
9. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia downregulates the expression of cell surface MICA without increasing soluble MICA in osteosarcoma cells in a HIF-1α-dependent manner.
Yamada N; Yamanegi K; Ohyama H; Hata M; Nakasho K; Futani H; Okamura H; Terada N
Int J Oncol; 2012 Dec; 41(6):2005-12. PubMed ID: 22992985
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the HDAC/Suv39/G9a pathway restores the expression of DNA damage-dependent major histocompatibility complex class I-related chain A and B in cancer cells.
Nakajima NI; Niimi A; Isono M; Oike T; Sato H; Nakano T; Shibata A
Oncol Rep; 2017 Aug; 38(2):693-702. PubMed ID: 28677817
[TBL] [Abstract][Full Text] [Related]
12. 2-deoxy D-glucose prevents cell surface expression of NKG2D ligands through inhibition of N-linked glycosylation.
Andresen L; Skovbakke SL; Persson G; Hagemann-Jensen M; Hansen KA; Jensen H; Skov S
J Immunol; 2012 Feb; 188(4):1847-55. PubMed ID: 22227571
[TBL] [Abstract][Full Text] [Related]
13. Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8
Hu J; Bernatchez C; Zhang L; Xia X; Kleinerman ES; Hung MC; Hwu P; Li S
Cancer Immunol Res; 2017 Apr; 5(4):300-311. PubMed ID: 28223282
[TBL] [Abstract][Full Text] [Related]
14. Induction of NKG2D ligand expression on tumor cells by CD8
Hu J; Xia X; Gorlick R; Li S
Oncogene; 2019 Dec; 38(49):7433-7446. PubMed ID: 31427736
[TBL] [Abstract][Full Text] [Related]
15. Rae1 drives NKG2D binding-dependent tumor development in mice by activating mTOR and STAT3 pathways in tumor cells.
Zhao P; Yang L; Li X; Lu W; Lu F; Wang S; Wang Y; Hua L; Cui C; Dong B; Yu Y; Wang L
Cancer Sci; 2020 Jul; 111(7):2234-2247. PubMed ID: 32333709
[TBL] [Abstract][Full Text] [Related]
16. A dual function of NKG2D ligands in NK-cell activation.
Cheney EE; Wise EL; Bui JD; Schreiber RD; Carayannopoulos LN; Spitzer D; Zafirova B; Polic B; Shaw AS; Markiewicz MA
Eur J Immunol; 2012 Sep; 42(9):2452-8. PubMed ID: 22740149
[TBL] [Abstract][Full Text] [Related]
17. NKG2D ligand overexpression in lupus nephritis correlates with increased NK cell activity and differentiation in kidneys but not in the periphery.
Spada R; Rojas JM; Pérez-Yagüe S; Mulens V; Cannata-Ortiz P; Bragado R; Barber DF
J Leukoc Biol; 2015 Mar; 97(3):583-98. PubMed ID: 25583577
[TBL] [Abstract][Full Text] [Related]
18. Activating receptor NKG2D targets RAE-1-expressing allogeneic neural precursor cells in a viral model of multiple sclerosis.
Weinger JG; Plaisted WC; Maciejewski SM; Lanier LL; Walsh CM; Lane TE
Stem Cells; 2014 Oct; 32(10):2690-701. PubMed ID: 24898518
[TBL] [Abstract][Full Text] [Related]
19. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
20. Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.
Di Modica M; Sfondrini L; Regondi V; Varchetta S; Oliviero B; Mariani G; Bianchi GV; Generali D; Balsari A; Triulzi T; Tagliabue E
Oncotarget; 2016 Jan; 7(1):255-65. PubMed ID: 26595802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
